TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 14 July 15, 2013
__________________________________________________________
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
UPCOMING MEETINGS & EVENTS
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 14 July 15, 2013
(The next issue will be on August 1, 2013)
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PAPERS IN PRESS
None Submitted for this issue.
__________________________________________________________None Submitted for this issue.
UPCOMING MEETINGS & EVENTS
General info on upcoming meetings of interest:
http://tf7.org/meetings.htm
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
Bao Y, Jin Y, Chivukula P, Zhang J, Liu Y, Liu J, . . .
Yu L (2013) Effect of PEGylation on biodistribution and gene silencing of
siRNA/lipid nanoparticle complexes. Pharm Res 30:342-351.
Ben-Hadj-Khalifa S, Nguyen P, Mahjoub T, Hezard N (2012)
Anticoagulant properties of the anti-inflammatory cytokine IL-10 in a factor
Xa-activated human monocyte model. Eur Cytokine Netw 23:87-92.
Brown SA, Barnes C, Curtin J, Dunkley S, Ockelford P,
Phillips J, . .
. Tran H (2012) How we use recombinant activated Factor
VII in patients with haemophilia A or B complicated by inhibitors. Working
group of hematology experts from Australia and New Zealand, Melbourne, April
2011. Intern Med J 42:1243-1250.
Cai X, Freedman SB, Witting PK (2013) Serum amyloid A
stimulates cultured endothelial cells to migrate and proliferate: inhibition by
the multi-kinase inhibitor BIBF1120. Clin Exp Pharmacol Physiol.
Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R
(2013) Coagulation Factors and Recurrence of Ischemic and Bleeding Adverse
Events in Patients with Acute Coronary Syndromes. Thromb Res.
Chaari M, Bouhlel R, Kallel S, Aidi Z, Makni F,
Gerotziafas GT, . . .
Kallel C (2012) [Post partum acquired hemophilia A with
fatal
outcome: a case report]. Ann Biol Clin (Paris)
70:741-746.
Frumkin K (2013) Rapid Reversal of Warfarin-Associated
Hemorrhage in the Emergency Department by Prothrombin Complex Concentrates. Ann
Emerg Med.
Giordano P, Lassandro G, Tesse R, Longo S, Valente F,
Cappiello AR, Coppola A (2013) Innovative use of recombinant activated factor
VII during physical rehabilitation in an Italian child with Glanzmann's
thromboasthenia. Blood Transfus 11:143-147.
Girolami A, Berti de Marinis G, Vettore S, Girolami B
(2013) Congenital FVII deficiency and pulmonary embolism: a critical appraisal
of all reported cases. Clin Appl Thromb Hemost 19:55-59.
Glunz PW, Zhang X, Zou Y, Delucca I, Nirschl AH, Cheng X,
. . .
Priestley ES (2013) Nonbenzamidine acylsulfonamide tissue
factor-factor VIIa inhibitors. Bioorg Med Chem Lett.
Gonzalez F, Kirwan JP, Rote NS, Minium J (2013) Elevated
circulating levels of tissue factor in polycystic ovary syndrome. Clin Appl
Thromb Hemost 19:66-72.
Hoving S, Heeneman S, Gijbels MJ, Te Poele JA, Visser N,
Cleutjens J, . . . Stewart FA (2012) Irradiation induces different inflammatory
and thrombotic responses in carotid arteries of wildtype C57BL/6J and
atherosclerosis-prone ApoE(-/-) mice. Radiother Oncol 105:365-370.
Ip HL, Chan AY, Ng KC, Soo YO, Wong LK (2013) Case
Report: A 70-Year-Old Man with Undiagnosed Factor VII Deficiency Presented with
Acute Ischemic Stroke. J Stroke Cerebrovasc Dis.
Kandane-Rathnayake RK, Willis CD, Beiles CB, Bourke BM,
Cameron PA, McCall P, Phillips LE (2013) Investigation of outcomes following
recombinant activated FVII use for refractory bleeding during abdominal aortic
aneurysm repair. Eur J Vasc Endovasc Surg 45:617-625.
Kidd L, Mackman N (2013) Prothrombotic mechanisms and
anticoagulant therapy in dogs with immune-mediated hemolytic anemia. J Vet
Emerg Crit Care (San Antonio) 23:3-13.
Korber MK, Langer E, Ziemer S, Perzborn E, Gericke C, von
Heymann C
(2013) Measurement and Reversal of Prophylactic and
Therapeutic Peak Levels of Rivaroxaban: An In Vitro Study. Clin Appl Thromb
Hemost.
Kortchinsky T, Vigue B, Samama CM (2013) [Reversal for
heparins and new anticoagulant treatments]. Ann Fr Anesth Reanim 32:37-49.
Kutcher ME, Ferguson AR, Cohen MJ (2013) A principal
component analysis of coagulation after trauma. J Trauma Acute Care Surg
74:1223-1229; discussion 1229-1230.
Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R,
Harwood C, . . .
Crook T (2013) Methylated tissue factor pathway inhibitor
2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol
133:1278-1285.
Maroney SA, Hansen KG, Mast AE (2013) Cellular expression
and biological activities of alternatively spliced forms of tissue factor
pathway inhibitor. Curr Opin Hematol.
Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG,
Laros-van Gorkom BA, Peyvandi F, van Heerde WL (2013) Increased volume of
distribution for recombinant activated factor VII and longer plasma-derived
factor VII half-life may explain their long lasting prophylactic effect. Thromb
Res.
Meade TW, Stirling Y (2012) The Northwick Park Heart
Studies:
contrasts between the two factor VII assays used. J
Thromb Haemost 10:482-484.
Mousa SA (2013) Comparative pharmacodynamic assessment of
the antiangiogenesis activity of heparin and low-molecular-weight heparin
fractions: structure-function relationship. Clin Appl
Thromb Hemost 19:48-54.
Nagakura T, Tabata K, Kira K, Hirota S, Clark R, Matsuura
F, Hiyoshi H (2013) Selective tissue factor/factor VIIa Inhibitor, ER-410660,
and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects
with a low risk of bleeding. Thromb Res.
Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg
AP, Meijers JC, . . . Lisman T (2013) Decreased tissue factor pathway inhibitor
(TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have
decreased protein S but normal TFPI plasma levels. Br J Haematol.
Rautou PE, Mackman N (2013) Microvesicles as risk markers
for venous thrombosis. Expert Rev Hematol 6:91-101.
Tagliaferri A, Franchini M (2013) The expanding role of
prophylaxis with recombinant activated factor VII. Blood Transfus 11:12-13.
Thompson JF (2013) Recombinant activated factor VII and
aortic surgery. Eur J Vasc Endovasc Surg 45:626.
Tian Y, Ma S, Lin B, Kou J, Yu B (2013) Anti-thrombotic
activity of DT-13, a saponin isolated from the root tuber of Liriope muscari.
Indian J Pharmacol 45:283-285.
Toutouzas K, Synetos A, Nikolaou C, Tsiamis E, Tousoulis
D, Stefanadis C (2012) Matrix metalloproteinases and vulnerable atheromatous
plaque. Curr Top Med Chem 12:1166-1180.
Winch PD, Naguib AN, Bradshaw JR, Galantowicz M, Tobias
JD (2013) Decreasing the need for transfusion: infant cardiac surgery using
hemodilution and recombinant factor VIIa. Pediatr Cardiol 34:119-124.
Winnik S, Stein S, Matter CM (2012) SIRT1 - an
anti-inflammatory pathway at the crossroads between metabolic disease and
atherosclerosis. Curr Vasc Pharmacol 10:693-696.
Yamashita A, Zhao Y, Zhao S, Matsuura Y, Sugita C,
Iwakiri T, . . .
Asada Y (2013) Arterial F-Fluorodeoxyglucose Uptake
Reflects Balloon Catheter-Induced Thrombus Formation and Tissue Factor
Expression via Nuclear Factor-kappaB in Rabbit Atherosclerotic Lesions. Circ J.
http://www.ncbi.nlm.nih.gov/pubmed/23832535
__________________________________________________________
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.
DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________
No comments:
Post a Comment